Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver disease progression. However, interferon-based treatments for HCV infection have significant toxicities, limiting treatment uptake.To assess the all-oral 3 direct-acting antiviral (3D)...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Mark Sulkowski, Joseph J. Eron, David Wyles, Roger Trinh, Jay Lalezari, Chia Wang, Jihad Slim, Laveeza Bhatti, Joseph Gathe, Peter Ruane, Richard Elion, Fritz Bredeek, Robert T. Brennan, Gary Blick, Amit Khatri, Krystal Gibbons, Yiran Hu, Linda Fredrick, Gretja Schnell, Edward Tam, Rakesh Tripathi, Barbara Da Silva‐Tillmann, Barbara McGovern, Andrew Campbell, Thomas Podsadecki
Format: Artigo
Jezik:angleščina
Izdano: 2015
Online dostop:https://doi.org/10.1001/jama.2015.1328
https://jamanetwork.com/journals/jama/articlepdf/2173265/joi150019.pdf
Oznake: Označite
Brez oznak, prvi označite!

Internet

https://doi.org/10.1001/jama.2015.1328
https://jamanetwork.com/journals/jama/articlepdf/2173265/joi150019.pdf

Podobne knjige/članki